Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Price, News & Analysis

Rubius Therapeutics logo

About Rubius Therapeutics Stock (NASDAQ:RUBY)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.02
$0.06
52-Week Range
$0.00
$0.38
Volume
755,858 shs
Average Volume
1.15 million shs
Market Capitalization
$5.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Remove Ads

Rubius Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

RUBY MarketRank™: 

Rubius Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Rubius Therapeutics.

  • Price to Book Value per Share Ratio

    Rubius Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for RUBY.
  • Dividend Yield

    Rubius Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rubius Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for RUBY.
  • Search Interest

    1 people have searched for RUBY on MarketBeat in the last 30 days.
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

How to Get the Exclusive Rubius Fortnite Drop
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Rubius Therapeutics Inc RUBY
RUBY - Rubius Therapeutics, Inc.
North American Morning Briefing: Alphabet, -2-
See More Headlines

RUBY Stock Analysis - Frequently Asked Questions

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its earnings results on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01.

Rubius Therapeutics (RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rubius Therapeutics investors own include Meta Platforms (META), Sorrento Therapeutics (SRNE), Pfizer (PFE), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Tesla (TSLA) and Athenex (ATNX).

Company Calendar

Last Earnings
11/08/2021
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
0.34

Miscellaneous

Free Float
85,687,000
Market Cap
$5.16 million
Optionable
Not Optionable
Beta
2.59
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RUBY) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners